The Morris Hepatoma (MH) and HepG2 cells were treated in vitro with sorafenib (1-10 ¦ÌM) and erlotinib (1-5 ¦ÌM) and evaluated for tumor cell viability, apoptosis, and target regulation. Antiangiogenic effects were studied by measuring VEGF levels, endothelial cell viability, apoptosis, migration, and the aortic ring assay.
In vivo, MH cells were implanted into the liver of syngeneic rats and treated with vehicle, sorafenib 5-10 mg/kg, erlotinib 10 mg/kg, and respective combinations.
In vitro, erlotinib downregulated p-ERK but showed no significant effect on tumor cell viability in MH and HEPG2 cells. Despite a similar target regulation, sorafenib significantly reduced cell viability of HCC cells by induction of apoptosis, in a dose-dependent manner (11 ¡À 5 % ; 20 ¡À 10 % ; 51 ¡À 5 % for sorafenib 1, 5, 10 ¦ÌM). No additional effect was observed upon combination with erlotinib.
Of note, erlotinib treatment resulted in endothelial cell migration and vascular sprouting of aortic rings through induction of VEGF mRNA and protein levels in endothelial and tumor cells, which was blocked by sorafenib. In vivo, erlotinib had no single agent antitumor activity, raised serum-VEGF levels, and lacked a synergistic effect in combination with sorafenib.
Erlotinib had no antitumor effect on HCC in vitro nor in vivo, but induced VEGF, which may reflect a resistance mechanism to erlotinib monotherapy. No improvement of sorafenib efficacy was observed upon combination with erlotinib.